Lipid-based nanoparticulate delivery systems for HER2-positive breast cancer immunotherapy

Nima Behravan, Fatemeh Zahedipour, Mahmoud Reza Jaafari, Thomas P. Johnston, Amirhossein Sahebkar

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)


Lipid-based nanoparticulate delivery platforms such as liposomes help overcome cell and tissue barriers and allow prolonged therapeutic plasma drug concentrations, simultaneous targeting of tumor tissue, and increased bioavailability of numerous drugs used for treatment of cancer. The human epidermal growth factor receptor, HER2, is an important player in the pathogenesis of breast cancer and is considered a potential cancer biomarker for the design of immunotherapeutics. HER2-positive breast cancer is found in up to 30% of breast cancer patients. Currently, a variety of lipid nanoparticulate systems are being evaluated in preclinical settings and in clinical trials for targeting HER2-positive breast cancer. Advances in functionalized anti-HER2 lipid nanoparticulates have demonstrated promise and may lead to the development of new nano-immunotherapy protocols against HER2 positive breast cancer. Here we present a review of the most up-to-date literature, including our own research, on the use of lipid nanoparticulate carriers in immunotherapy of HER2-positive breast cancer.

Original languageEnglish
Article number120294
JournalLife Sciences
Publication statusPublished - 15 Feb 2022


Dive into the research topics of 'Lipid-based nanoparticulate delivery systems for HER2-positive breast cancer immunotherapy'. Together they form a unique fingerprint.

Cite this